Alternative Views On Setting Clinical Trial Futility Criteria
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2014/08/11
-
Indian UGC (journal)
-
Refrences18
-
Citations27
-
Paul Gallo Novartis Pharmaceuticals, East Hanover, New Jersey, USA
-
Lu Mao Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA
-
Vivian H. Shih Novartis Pharmaceuticals, East Hanover, New Jersey, USA
Cite
Gallo, Paul, et al. “Alternative Views On Setting Clinical Trial Futility Criteria”. Journal of Biopharmaceutical Statistics, vol. 24, no. 5, 2014, pp. 976-93, https://doi.org/10.1080/10543406.2014.932285.
Gallo, P., Mao, L., & Shih, V. H. (2014). Alternative Views On Setting Clinical Trial Futility Criteria. Journal of Biopharmaceutical Statistics, 24(5), 976-993. https://doi.org/10.1080/10543406.2014.932285
Gallo P, Mao L, Shih VH. Alternative Views On Setting Clinical Trial Futility Criteria. Journal of Biopharmaceutical Statistics. 2014;24(5):976-93.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
Science
Mathematics
Probabilities
Mathematical statistics
You May Also Like
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies
- Sample size of 12 per group rule of thumb for a pilot study
- Guidelines for accurate EC50/IC50 estimation
- Quantifying heterogeneity in a meta‐analysis
- Multiple imputation using chained equations: Issues and guidance for practice
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Group sequential and adaptive methods—Topics with applications to clinical trials | 2011 | |||
| Group Sequential Methods With Applications to Clinical Trials | 2000 | |||
A flexible futility monitoring method with time-varying conditional power boundary | Clinical Trials |
| 8 | 2010 |
| Monitoring clinical trials: Conditional or predictive power? | Controlled Clinical Trials | 176 | 1986 | |
Assessment of futility in clinical trials | Pharmaceutical Statistics |
| 63 | 2006 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Beta spending function based on conditional power in group sequential design | Biometrical Journal |
| 2024 | |
Optimal futility stopping boundaries for binary endpoints | BMC Medical Research Methodology |
| 2024 | |
Bayesian hierarchical modeling in interim futility analysis for two parallel clinical trials | Statistics in Medicine |
| 2023 | |
| Challenges in Implementing Futility Schemes, with Reference to Aducanumab | Therapeutic Innovation & Regulatory Science |
| 1 | 2023 |
| Epistemic uncertainty in Bayesian predictive probabilities | Journal of Biopharmaceutical Statistics |
| 2023 |
Citations Analysis
The category
Science: Mathematics: Probabilities. Mathematical statistics 17
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled On the Use of Co-Data in Clinical Trials and was published in 2016. The most recent citation comes from a 2024 study titled Beta spending function based on conditional power in group sequential design. This article reached its peak citation in 2023, with 5 citations. It has been cited in 13 different journals, 23% of which are open access. Among related journals, the Statistics in Biopharmaceutical Research cited this research the most, with 6 citations. The chart below illustrates the annual citation trends for this article.